Ads
related to: bharat biotech covid-19
Search results
The era of needle-free COVID vaccines may be beginning as India approves its first nasal spray
Fortune via Yahoo Finance· 2 years agoIndia’s drug regulator authorized the country’s first nasal spray vaccine on Tuesday, marking a big...
Bharat Biotech's COVID-19 nasal vaccine approved for restricted use in India
Reuters via Yahoo News· 2 years agoNEW DELHI (Reuters) - Bharat Biotech's COVID-19 recombinant nasal vaccine has been approved by the Indian drug regulator, the country's health minister Mansukh Mandaviya tweeted on Tuesday.
India and China clear needle-free COVID-19 vaccines
Associated Press via Yahoo News· 2 years agoIndia and China have cleared a new approach in COVID-19 vaccination — two needle-free options, one a squirt in the nose and the other inhaled through the...
Ocugen (OCGN) Covaxin Studies Clinical Hold Lifted by FDA
Zacks via Yahoo Finance· 2 years agoShares of Ocugen, Inc. OCGN gained in pre-market on May 23 after the company announced that the FDA...
Ocugen-Bharat Biotech COVID vaccine meets main goals in U.S. trial
Reuters via Yahoo News· 1 year agoThe vaccine, sold under brand name Covaxin, showed an immune response in individuals who had not...
Without a nasal vaccine, the U.S. edge in fighting Covid is on the line
Politico via Yahoo News· 2 years agoBiden administration officials are raising concerns that the slow pace of developing a nasal vaccine...
U.S. drug regulator lifts clinical hold on Ocugen's COVID vaccine trial
Reuters via Yahoo News· 2 years agoThe Food and Drug Administration paused the trials of the shot, Covaxin, in April after an...
Bharat Biotech nears phase III trials for tuberculosis vaccine
Investing.com via Yahoo Finance· 8 months agoBharat Biotech International, an Indian vaccine manufacturer, is on the verge of launching phase III clinical trials for its Tuberculosis (TB) vaccine candidate, Mycobacterium Tuberculosis Vaccine ...
FDA Removes Clinical Hold On Ocugen's COVID Vaccine Trial
Benzinga via Yahoo Finance· 2 years agoThe FDA has lifted the clinical hold on Ocugen Inc's (NASDAQ: OCGN) Phase 2/3 trial, OCU-002, for...
Ocugen's Partner COVID-19 Vaccine Covaxin Shows Encouraging Action In Children Below 18 Years
Benzinga via Yahoo Finance· 2 years agoOcugen Inc (NASDAQ: OCGN) announced the publication of positive pediatric Phase 2/3 study results in...